Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 4
1963 1
1965 5
1966 1
1967 4
1968 9
1969 3
1970 4
1971 15
1972 11
1973 6
1974 4
1975 2
1976 3
1977 2
1978 8
1979 1
1980 10
1981 4
1982 8
1983 3
1984 4
1985 4
1986 3
1987 1
1988 2
1989 4
1990 4
1991 2
1992 2
1993 1
1994 1
1996 2
1997 4
1998 8
1999 5
2000 6
2001 5
2002 3
2003 8
2004 7
2005 4
2006 5
2007 3
2008 4
2009 9
2010 9
2011 12
2012 8
2013 9
2014 4
2015 8
2016 7
2017 1
2018 3
2019 3
2020 2
2021 4
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM; PROMISE Study group. Nichols DP, et al. Am J Respir Crit Care Med. 2022 Mar 1;205(5):529-539. doi: 10.1164/rccm.202108-1986OC. Am J Respir Crit Care Med. 2022. PMID: 34784492 Free PMC article.
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O'Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH; SIMPLIFY Study Group. Mayer-Hamblett N, et al. Lancet Respir Med. 2023 Apr;11(4):329-340. doi: 10.1016/S2213-2600(22)00434-9. Epub 2022 Nov 4. Lancet Respir Med. 2023. PMID: 36343646 Free PMC article. Clinical Trial.
The emergence of agbiogenerics.
Jefferson DJ, Graff GD, Chi-Ham CL, Bennett AB. Jefferson DJ, et al. Among authors: graff gd. Nat Biotechnol. 2015 Aug;33(8):819-23. doi: 10.1038/nbt.3306. Nat Biotechnol. 2015. PMID: 26252137 No abstract available.
Palivizumab and Long-term Outcomes in Cystic Fibrosis.
Fink AK, Graff G, Byington CL, Loeffler DR, Rosenfeld M, Saiman L. Fink AK, et al. Among authors: graff g. Pediatrics. 2019 Jul;144(1):e20183495. doi: 10.1542/peds.2018-3495. Pediatrics. 2019. PMID: 31239289
Oriented nanostructures for energy conversion and storage.
Liu J, Cao G, Yang Z, Wang D, Dubois D, Zhou X, Graff GL, Pederson LR, Zhang JG. Liu J, et al. Among authors: graff gl. ChemSusChem. 2008;1(8-9):676-97. doi: 10.1002/cssc.200800087. ChemSusChem. 2008. PMID: 18693284 Review.
The rise and fall of innovation in biofuels.
Albers SC, Berklund AM, Graff GD. Albers SC, et al. Among authors: graff gd. Nat Biotechnol. 2016 Aug 9;34(8):814-21. doi: 10.1038/nbt.3644. Nat Biotechnol. 2016. PMID: 27504772 No abstract available.
274 results